

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 September 2010 (23.09.2010)

PCT

(10) International Publication Number
WO 2010/108060 A1

(51) International Patent Classification:
A01N 31/08 (2006.01) *A61K 31/05* (2006.01)

(21) International Application Number:
PCT/US2010/027905

(22) International Filing Date:
19 March 2010 (19.03.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/202,635 20 March 2009 (20.03.2009) US
61/213,313 28 May 2009 (28.05.2009) US

(71) Applicant (for all designated States except US):
STIEFEL LABORATORIES, INC. [US/US]; 255 Alhambra Circle, Coral Gables, FL 22134 (US).

(71) Applicant (for all designated States except US):
STIEFEL RESEARCH AUSTRALIA PTY LTD [AU/AU]; 8 Marco Court, Rowville, VIC 3178 (AU).

(71) Applicant (for US only): **HOFLAND, Hans** [US/US]; 3160 Porter Dr, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LENN, Jon** [US/US]; 3160 Porter Dr, Palo Alto, CA 94304 (US). **HUNT, Barry** [AU/AU]; 8 Macro Court, Rowville, VIC 3178 (AU). **HSIA, Edward** [US/US]; 3160 Porter Dr, Palo Alto, CA 94304 (US).

(74) Agents: **DINNER, Dara, L.** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: FATTY ACID MONOGLYCERIDE COMPOSITIONS

(57) Abstract: The present invention relates to a method of treating a fungal condition caused by *T. rubrum*, by administering a composition comprising a fatty acid monoester of glycerol. According to an embodiment, the fatty acid monoester of glycerol is 1-monocaprin. According to another embodiment, the fungal condition is onychomycosis



WO 2010/108060 A1